0001493152-26-030335.txt : 20260626 0001493152-26-030335.hdr.sgml : 20260626 20260626170526 ACCESSION NUMBER: 0001493152-26-030335 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260626 DATE AS OF CHANGE: 20260626 EFFECTIVENESS DATE: 20260626 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Edesa Biotech, Inc. CENTRAL INDEX KEY: 0001540159 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-588852 FILM NUMBER: 261130310 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 100 SPY COURT CITY: MARKHAM PROVINCE COUNTRY: A6 BUSINESS PHONE: (905) 475-1234 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 100 SPY COURT CITY: MARKHAM PROVINCE COUNTRY: A6 FORMER COMPANY: FORMER CONFORMED NAME: Stellar Biotechnologies, Inc. DATE OF NAME CHANGE: 20120120 D 1 primary_doc.xml X0708 D LIVE 0001540159 Edesa Biotech, Inc. 100 SPY COURT MARKHAM A6 ONTARIO, CANADA L3R 5H6 289-800-9600 BRITISH COLUMBIA, CANADA None Stellar Biotechnologies, Inc. Corporation true Sean MacDonald 100 Spy Court Markham A6 ONTARIO, CANADA L3R 5H6 Director Pardeep Nijhawan 100 Spy Court Markham A6 ONTARIO, CANADA L3R 5H6 Executive Officer Director Carlo Sistilli 100 Spy Court Markham A6 ONTARIO, CANADA L3R 5H6 Director Michael Brooks 100 Spy Court Markham A6 ONTARIO, CANADA L3R 5H6 Executive Officer Peter Weiler 100 Spy Court Markham A6 ONTARIO, CANADA L3R 5H6 Executive Officer Joan Chypyha 100 Spy Court Markham A6 ONTARIO, CANADA L3R 5H6 Director Charles Olson 100 Spy Court Markham A6 ONTARIO, CANADA L3R 5H6 Director Patrick Marshall 100 Spy Court Markham A6 ONTARIO, CANADA L3R 5H6 Director David Liu 100 Spy Court Markham A6 ONTARIO, CANADA L3R 5H6 Director Biotechnology Decline to Disclose 06b false 2026-06-16 false true true false 0 3500000 3499986 14 false 4 0 0 0 true The proceeds from the offering will be used for working capital and general corporate purposes. false Edesa Biotech, Inc. /s/ Peter Weiler Peter Weiler Chief Financial Officer 2026-06-26